CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

All Clinical Trials for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01949337 ↗	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer	Active, not recruiting	Astellas Pharma US, Inc.	Phase 3	2014-01-22	This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
NCT01949337 ↗	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer	Active, not recruiting	Biologics, Inc.	Phase 3	2014-01-22	This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
NCT01949337 ↗	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer	Active, not recruiting	Medivation, Inc.	Phase 3	2014-01-22	This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
NCT01949337 ↗	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2014-01-22	This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
NCT01949337 ↗	Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer	Active, not recruiting	Alliance for Clinical Trials in Oncology	Phase 3	2014-01-22	This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
NCT02304757 ↗	99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis	Completed	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	N/A	2015-01-01	Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis. Therefore, the investigators try to investigate the effects of 99Tc-MDP,alendronate sodium in postmenopausal women with DTC under TSH suppression and osteoporosis.
NCT05000086 ↗	A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis	Completed	Chengdu Yunke Pharmaceutical Co., Ltd.	Phase 4	2019-06-01	This study is aim to evaluate the efficacy and safety of technetium [99Tc] methylene diphosphonate (99Tc-MDP, trade name: Yunke) in the treatment of psoriatic arthritis.

Clinical Trial Conditions for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

Condition Name

Condition Name for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Intervention	Trials
Adenocarcinoma of the Prostate	1
Arthritis, Psoriatic	1
Differentiated Thyroid Cancer	1
Hormone-resistant Prostate Cancer	1

Condition MeSH

Condition MeSH for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Intervention	Trials
Arthritis	1
Thyroid Neoplasms	1
Thyroid Diseases	1
Osteoporosis	1

Clinical Trial Locations for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

Trials by Country

Trials by Country for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Location	Trials
United States	49
Canada	6
China	2
Puerto Rico	1

Trials by US State

Trials by US State for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Location	Trials
New Hampshire	1
Nevada	1
Nebraska	1
Montana	1
Missouri	1

Clinical Trial Progress for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

Clinical Trial Phase

Clinical Trial Phase for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
N/A	1

Clinical Trial Status

Clinical Trial Status for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Clinical Trial Phase	Trials
Completed	2
Active, not recruiting	1

Clinical Trial Sponsors for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

Sponsor Name

Sponsor Name for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Sponsor	Trials
Biologics, Inc.	1
Medivation, Inc.	1
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Sponsor	Trials
Other	4
Industry	3
NIH	1

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT: Clinical Trials Update, Market Analysis, and Projections

Last updated: April 25, 2026

What is the product and what does it do?

Technetium Tc 99m diphosphonate-tin kit is a radiopharmaceutical diagnostic kit used to prepare Tc-99m labeled diphosphonate after elution/labeling. The labeled agent is used primarily for bone imaging in nuclear medicine workflows (bone scintigraphy), including routine outpatient and inpatient diagnostic pathways.

Because the drug is a kit for radiolabeling rather than a systemically dosed therapeutic drug, the commercial story is driven by:

• Nuclear medicine procedure volumes (bone scan demand)
• Hospital imaging capacity and throughput
• Cold-chain and radiopharmacy logistics
• Supply continuity of Tc-99m generator-derived material
• Regulatory and compendial acceptance in radiopharmacy practice

What is the clinical trials update status?

No complete, public, global trial record set is available in the accessible record set to produce an accurate, source-backed “clinical trials update” (phase-by-phase pipeline, recruiting status, endpoints, and trial counts) specific to technetium Tc 99m diphosphonate-tin kit as a named kit product.

How does the market structure for Tc-99m bone imaging kits work?

The market behaves like a procedure-driven consumables and radiopharmacy supply segment:

Demand drivers

• Bone scan volumes driven by:
  • Metastatic cancer evaluation workflows
  • Osteoporosis and fracture evaluation pathways (where used)
  • Unexplained pain evaluation and other musculoskeletal indications
• Tc-99m generator availability and reliability (upstream supply)
• Radiopharmacy throughput and kit conversion/labeling performance

Competitive and substitution dynamics

Key substitutes at the “test” level include other Tc-99m bone-seeking agents and alternative imaging modalities, such as:

• Other Tc-99m labeled phosphonates
• CT/MRI (site-specific alternative workups depending on clinical pathway)
• PET agents in advanced oncology settings (practice varies by country, reimbursement, and clinical guidelines)

At the kit level, competition is constrained by:

• Labeling chemistry compatibility with radiopharmacy practice
• Regulatory approval in each country
• Institutional procurement history
• Availability and delivery reliability

What is the current market snapshot and segmentation basis?

A precise quantitative market snapshot (global kit revenue, unit volumes, or by-country shares) requires product-level databases and country-by-country pricing and reimbursement data that are not available in the accessible record set to generate a complete, accurate projection. This prevents building a defensible numeric base for “market analysis and projection” tied to this specific kit name.

What can be stated as actionable drivers for investors and R&D operators, based on how this category sells and gets used:

• Revenue is correlated with imaging procedures, not patient populations in the same way as therapeutics.
• Pricing is constrained by hospital procurement processes and substitution options within radiopharmacy formularies.
• Margin stability depends on supply reliability of Tc-99m labeling reagents and kit manufacturing continuity.

What does the projection outlook depend on?

Even without numeric market sizing, the projection framework is consistent for Tc-99m bone imaging kits:

Base-case growth components

• Stable to modest growth in diagnostic imaging demand
• Capacity expansion in radiology and nuclear medicine services
• Improved radiopharmacy utilization and throughput
• Ongoing clinical reliance on bone scintigraphy in oncology pathways

Downside components

• Procedure substitution toward PET or CT/MRI in specific indications
• Tc-99m supply shocks or generator disruptions that affect the entire class
• Regulatory/label changes that shift indication coverage or protocol usage
• Inventory rationing dynamics at hospital and wholesaler levels during supply constraints

Upside components

• Reimbursement improvements for bone scintigraphy
• Higher uptake in metastatic staging pathways where bone scans remain cost-effective versus alternatives
• Formulary wins in large hospital networks

What are the main commercial risks for a Tc-99m diphosphonate-tin kit?

For kits in this category, the primary business risks are operational and supply-chain driven rather than mechanistic.

1) Upstream supply risk

• Tc-99m availability depends on generator supply chains. Any disruption impacts kit utilization.

2) Regulatory continuity

• Radiopharmaceutical approvals, labeling, and manufacturing compliance require continuous quality systems and facility performance.

3) Substitution risk

• Other Tc-99m phosphonate products can replace usage depending on local procurement, availability, and perceived performance.

4) Market access and pricing pressure

• Hospital procurement and tender processes can compress pricing even when demand holds steady.

What is the action plan for R&D, licensing, and investment screening?

Given the kit nature, screening emphasizes manufacturing and regulatory readiness plus supply reliability.

R&D and product stewardship priorities

• Process consistency for the labeled agent performance within radiopharmacy constraints
• Stability and labeling robustness for routine preparation workflows
• Compatibility with automated and manual radiopharmacy processes (where applicable)

Commercial diligence checklist

• Supply continuity track record (deliveries, lead times, fill-rate)
• Regulatory status stability across target geographies
• Institutional formulary adoption history (tenders, network conversions)
• Evidence of comparable imaging performance in real-world workflows (kit labeling and post-labeling characteristics)

Key Takeaways

• Technetium Tc 99m diphosphonate-tin kit is a procedure-driven radiopharmaceutical kit used for bone scintigraphy after Tc-99m labeling.
• A source-backed global clinical trials update for this exact kit name cannot be produced from the accessible record set.
• Market outlook for Tc-99m bone imaging kits is driven by imaging procedure volumes, Tc-99m generator supply reliability, and radiopharmacy procurement and substitution dynamics rather than by patient pool expansion typical of therapeutics.
• Investment and commercialization planning should focus on supply continuity, regulatory continuity, and formulary adoption, with downside sensitivity to Tc-99m supply and practice substitution to alternative imaging.

FAQs

1) Is this a therapeutic drug or a diagnostic kit?
It is a diagnostic radiopharmaceutical kit used to prepare Tc-99m labeled diphosphonate for bone imaging.

2) What drives demand for this kit?
Demand is primarily driven by bone scintigraphy procedure volumes and radiopharmacy utilization in nuclear medicine departments.

3) What is the biggest external risk for the category?
Tc-99m generator and upstream supply continuity, which can constrain available doses and indirectly suppress kit utilization.

4) Can other products substitute for it?
Yes. Competing Tc-99m phosphonate agents and, in some workflows, alternative imaging modalities can substitute depending on country practice and reimbursement.

5) Does the clinical pipeline matter like it does for therapeutics?
Less so. For this kit category, commercial outcomes depend more on regulatory continuity, manufacturing reliability, and procedure demand than on mechanistic clinical development.

---

References

[1] FDA. Drugs@FDA: FDA Approved Drug Products (Search tool for radiopharmaceutical products and related labeling records). U.S. Food and Drug Administration.
[2] IAEA. Nuclear Medicine Resources and Tc-99m Background. International Atomic Energy Agency.
[3] USP. Radiopharmaceutical compounding and related standards for Tc-99m preparations (compendial context). United States Pharmacopeia.
[4] WHO. Nuclear medicine and radionuclide supply context (Tc-99m generator dependency overview). World Health Organization.